BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
BRISTOL MYERS SQUIBB CO revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product sales | $88.09B | $83.67B | $73.68B | $69.63B | $67.90B | $60.02B | – | – | – | – | 182.8% | +5.3% |
| Net product sales | $46.76B | $46.78B | $43.78B | $44.67B | $45.06B | – | – | – | – | – | 97.0% | -0.0% |
| Growth Portfolio | $26.41B | $22.56B | $19.37B | $16.76B | – | – | – | – | – | – | 54.8% | +17.0% |
| Legacy Portfolio | $21.79B | $25.74B | $25.64B | $29.40B | – | – | – | – | – | – | 45.2% | -15.4% |
| Eliquis | $14.44B | $13.33B | $12.21B | $11.79B | $10.76B | $9.17B | $7.93B | $6.44B | $4.87B | $3.34B | 30.0% | +8.3% |
| Opdivo | $10.05B | $9.30B | $9.01B | $8.25B | $7.52B | $6.99B | $7.20B | $6.74B | $4.95B | $3.77B | 20.9% | +8.0% |
| Orencia | $3.71B | $3.68B | $3.60B | $3.46B | $3.31B | $3.16B | $2.98B | $2.71B | $2.48B | $2.27B | 7.7% | +0.6% |
| Revlimid | $2.95B | $5.77B | $6.10B | $9.98B | $12.82B | $12.11B | $1.30B | $0 | $0 | – | 6.1% | -48.9% |
| Yervoy | $2.90B | $2.53B | $2.24B | $2.13B | $2.03B | $1.68B | $1.49B | $1.33B | $1.24B | $1.05B | 6.0% | +14.6% |
| Pomalyst/Imnovid | $2.73B | $3.55B | $3.44B | $3.50B | $3.33B | $3.07B | $322.00M | $0 | $0 | – | 5.7% | -22.9% |
| Reblozyl | $2.33B | $1.77B | $1.01B | $717.00M | $551.00M | $274.00M | $0 | $0 | – | – | 4.8% | +31.2% |
| Other Growth products | $1.92B | $1.64B | $1.21B | $1.09B | – | – | – | – | – | – | 4.0% | +17.1% |
| Alliance and other revenues | $1.44B | $1.52B | $1.23B | $1.49B | $1.33B | – | – | – | – | – | 3.0% | -5.5% |
| Breyanzi | $1.36B | $747.00M | $364.00M | $182.00M | $87.00M | $0 | $0 | – | – | – | 2.8% | +81.8% |
| Opdualag | $1.19B | $928.00M | $627.00M | $252.00M | $0 | $0 | – | – | – | – | 2.5% | +27.7% |
| Camzyos | $1.07B | $602.00M | $231.00M | $24.00M | $0 | $0 | – | – | – | – | 2.2% | +77.4% |
| Other revenues | $992.00M | $1.04B | $620.00M | $746.00M | $614.00M | $582.00M | – | – | – | – | 2.1% | -4.9% |
| Other Legacy products | $798.00M | $925.00M | $962.00M | $1.16B | – | – | – | – | – | – | 1.7% | -13.7% |
| Zeposia | $577.00M | $566.00M | $434.00M | $250.00M | $134.00M | $12.00M | $0 | $0 | – | – | 1.2% | +1.9% |
| Sprycel | $493.00M | $1.29B | $1.93B | $2.17B | $2.12B | $2.14B | $2.11B | $2.00B | $2.01B | $1.82B | 1.0% | -61.7% |
| Alliance revenues | $447.00M | $479.00M | $608.00M | $742.00M | $716.00M | $615.00M | – | – | – | – | 0.9% | -6.7% |
| Abecma | $427.00M | $406.00M | $472.00M | $388.00M | $164.00M | $0 | $0 | – | – | – | 0.9% | +5.2% |
| Abraxane | $368.00M | $875.00M | $1.00B | $811.00M | $1.18B | $1.25B | $166.00M | $0 | $0 | – | 0.8% | -57.9% |
| Sotyktu | $291.00M | $246.00M | $170.00M | $8.00M | $0 | $0 | – | – | – | – | 0.6% | +18.3% |
| Opdivo Qvantig | $238.00M | $0 | $0 | – | – | – | – | – | – | – | 0.5% | – |
| Krazati | $205.00M | $126.00M | $0 | $0 | – | – | – | – | – | – | 0.4% | +62.7% |
| Cobenfy | $155.00M | $10.00M | $0 | $0 | – | – | – | – | – | – | 0.3% | +1450.0% |
| Sustiva Franchise [Member] | – | – | – | – | – | – | – | $283.00M | $729.00M | $1.07B | – | – |
| Reyataz [Member] | – | – | – | – | – | – | – | $427.00M | $698.00M | $912.00M | – | – |
| Baraclude [Member] | – | – | – | – | – | $447.00M | $555.00M | $744.00M | $1.05B | $1.19B | – | – |
| Abilify [Member] | – | – | – | – | – | – | – | – | – | $128.00M | – | – |
| Hepatitis C Portfolio [Member] | – | – | – | – | – | – | – | $17.00M | $406.00M | $1.58B | – | – |
| Empliciti | – | – | – | $296.00M | $334.00M | $381.00M | $357.00M | $247.00M | $231.00M | $150.00M | – | – |
| Mature and other brands | – | – | $1.90B | $2.05B | $2.23B | $2.22B | $2.29B | $2.36B | $3.95B | $2.27B | – | – |
| Vidaza [Member] | – | – | – | – | – | $455.00M | $58.00M | $0 | $0 | – | – | – |
| Inrebic | – | – | $110.00M | $85.00M | $74.00M | $55.00M | $5.00M | $0 | $0 | – | – | – |
| Onureg | – | – | $168.00M | $124.00M | $73.00M | $17.00M | $0 | $0 | – | – | – | – |
| Net product sales | – | – | – | $44.67B | $45.06B | $41.32B | – | – | – | – | – | – |
| Alliance and other revenues | – | – | – | $1.49B | $1.33B | $1.20B | – | – | – | – | – | – |
| Total Recent LOE Products | – | – | $7.10B | $10.79B | $14.00B | – | – | – | – | – | – | – |
| In-line products and new product portfolio | – | – | $37.91B | $35.37B | $32.38B | – | – | – | – | – | – | – |
| In-line products | – | – | $34.32B | $33.34B | $31.30B | – | – | – | – | – | – | – |
| New product portfolio | – | – | $3.59B | $2.03B | $1.08B | – | – | – | – | – | – | – |
| Augtyro | – | $38.00M | $1.00M | $0 | $0 | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S [Member] | $33.28B | $34.11B | $31.21B | $31.50B | $29.21B | $26.58B | $15.34B | $12.59B | $11.36B | $10.72B | 69.1% | -2.4% |
| International | $13.83B | $13.20B | $13.10B | $13.83B | – | – | – | – | – | – | 28.7% | +4.8% |
| Other | $1.09B | $996.00M | $699.00M | $834.00M | $852.00M | $631.00M | $524.00M | $584.00M | $553.00M | $528.00M | 2.3% | +9.1% |
| Europe | – | – | – | – | – | – | – | – | $4.99B | $4.22B | – | – |
| Rest of the World | – | – | – | – | $5.63B | $5.46B | $4.01B | $3.73B | $3.88B | $3.96B | – | – |
| International | – | – | – | $13.50B | $16.32B | $15.31B | $6.27B | $5.66B | $4.99B | $4.22B | – | – |
| International | – | – | $12.75B | $13.50B | $16.32B | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Bristol Myers Squibb's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.